Literature DB >> 23098555

Antimicrobial resistance patterns and corresponding multilocus sequence types of the Campylobacter jejuni isolates from human diarrheal samples.

Eunju Shin1, Younghee Oh, Moosang Kim, Jihun Jung, Yeonhee Lee.   

Abstract

A total of 121 Campylobacter isolates from 4,788 humans with gastroenteritis were identified and characterized by biochemical detection methods, polymerase chain reaction, and multilocus sequence typing (MLST). These samples were obtained during a 3-year period, from January 2007 to December 2009, using the National Notifiable Diseases Surveillance System at the Research Institute of Public Health and Environment in Seoul Metropolitan, Korea. Antimicrobial susceptibilities of the bacterium were also determined with the agar dilution method. All 121 isolates were identified as Campylobacter jejuni, with all (100%) of them having two virulence genes (ceuE and cadF) and a toxin gene (cdtB). Twenty-three different sequence types (STs), including 9 new STs, were determined by MLST. The most prevalent ST and clonal complex (CC) observed in this study were ST-45 (28.9%) and ST-45 CC (53.7%), respectively. Percentages of antimicrobial-resistant isolates were 1.9% for ampicillin, 0.8% for chloramphenicol, 24% for ciprofloxacin, 46.3% for enrofloxacin, 0.8% for erythromycin, 6.6% for gentamicin, and 46.3% for tetracycline. This study demonstrated that the majority of the Campylobacter isolates obtained from human samples in Korea were C. jejuni with ST-45 CC, which has been detected mainly in broilers worldwide, and all strains with new STs were uniformly resistant to enrofloxacin and tetracycline. This study indicates that broilers may be a breeding ground for bacteria as well as an important potential source of human campylobacteriosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23098555     DOI: 10.1089/mdr.2012.0099

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  7 in total

1.  First Report and Molecular Characterization of a Campylobacter jejuni Isolate with Extensive Drug Resistance from a Travel-Associated Human Case.

Authors:  Eunju Shin; Hyunjin Hong; Younghee Oh; Yeonhee Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

2.  Antimicrobial susceptibility profiles and molecular typing of Campylobacter jejuni and Campylobacter coli isolates from ducks in South Korea.

Authors:  Bai Wei; Se-Yeoun Cha; Min Kang; Jae-Hee Roh; Hye-Suk Seo; Ran-Hee Yoon; Hyung-Kwan Jang
Journal:  Appl Environ Microbiol       Date:  2014-09-26       Impact factor: 4.792

Review 3.  Clinical importance and epidemiology of quinolone resistance.

Authors:  Eu Suk Kim; David C Hooper
Journal:  Infect Chemother       Date:  2014-12-29

4.  Epidemiological relationships of Campylobacter jejuni strains isolated from humans and chickens in South Korea.

Authors:  Jae-Young Oh; Yong-Kuk Kwon; Bai Wei; Hyung-Kwan Jang; Suk-Kyung Lim; Cheon-Hyeon Kim; Suk-Chan Jung; Min-Su Kang
Journal:  J Microbiol       Date:  2016-12-30       Impact factor: 3.422

5.  Antibiotic Resistance of Campylobacter Species in a Pediatric Cohort Study.

Authors:  Francesca Schiaffino; Josh M Colston; Maribel Paredes-Olortegui; Ruthly François; Nora Pisanic; Rosa Burga; Pablo Peñataro-Yori; Margaret N Kosek
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

6.  Local accessory gene sharing among Egyptian Campylobacter potentially promotes the spread of antimicrobial resistance.

Authors:  Shaimaa F Mouftah; Ben Pascoe; Jessica K Calland; Evangelos Mourkas; Naomi Tonkin; Charlotte Lefevre; Danielle Deuker; Sunny Smith; Harry Wickenden; Matthew D Hitchings; Samuel K Sheppard; Mohamed Elhadidy
Journal:  Microb Genom       Date:  2022-06

7.  Identification of a novel G2073A mutation in 23S rRNA in amphenicol-selected mutants of Campylobacter jejuni.

Authors:  Licai Ma; Zhangqi Shen; Gaowa Naren; Hui Li; Xi Xia; Congming Wu; Jianzhong Shen; Qijing Zhang; Yang Wang
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.